gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 13 Oct 2015.

V-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog

erbB-2, HER2, c-erbB-2, HER-2/neu
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: HAD, CAN, EGFR, AGE, Akt
Papers using erbB-2 antibodies
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium.
Peterlongo Paolo, In PLoS ONE, 2010
... HER2 positivity was determined by IHC 3+ (HerceptTest, DAKO, Denmark) or fluorescence ...
Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray
Lazutka Juozas et al., In Diagnostic Pathology, 2010
... Paraffin sections of the TMAs were cut for IHC (3 μm-thick) and HER2 FISH testing (4 μm-thick).IHC was performed on the TMA sections using Ultraview DAB detection kit on Ventana BenchMark XT staining system (Ventana Medical Systems, Tucson, Arizona, USA) [ ...
Genomic profiles specific to patient ethnicity in lung adenocarcinoma
Lamy Pierre-Jean et al., In Breast Cancer Research : BCR, 2010
... Patients with primary HER-2-negative breast cancer were initially selected based on the level of HER-2 protein expression by IHC using the A485 monoclonal antibody (Dako A/S, Glostrup, Denmark) ...
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
Shu Xiao Ou et al., In BMC Cancer, 2009
... The modified staining protocol for HER2/PR based on the DAKO EnVision™ G|2 Doublestain kit.
Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome
Serrano María José et al., In Breast Cancer Research : BCR, 2009
... HER2 status was determined by IHC by using Herceptest (Dako) in all patients and ...
more suppliers
Papers on erbB-2
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line.
Mouret-Reynier et al., In Oncology, 13 Nov 2015
BACKGROUND: Everolimus (Afinitor®) plus exemestane are indicated for hormone receptor-positive, HER2/neu-negative metastatic breast cancer (MBC), in menopausal women without symptomatic visceral disease after recurrence or progression following aromatase inhibitors.
Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute.
Hainsworth et al., Nashville, United States. In Breast Cancer Res Treat, 12 Nov 2015
Patients with untreated HER2-negative MBC were randomized (1:1) to receive 28-day cycles of paclitaxel 90 mg/m(2) IV (days 1, 8, and 15) and bevacizumab 10 mg/kg IV (days 1, 15) with either everolimus 10 mg (Arm 1) or placebo (Arm 2) daily.
Endocrine resistance in breast cancer - an overview and update.
Dixon et al., Washington, D.C., United States. In Mol Cell Endocrinol, 08 Nov 2015
More women eventually die from ERα+ breast cancer than from either HER2+ disease (almost half of which also express ERα) and/or from triple negative breast cancer (ERα-negative, progesterone receptor-negative, and HER2-negative).
The genomic landscape of response to EGFR blockade in colorectal cancer.
Velculescu et al., Torino, Italy. In Nature, 08 Nov 2015
In addition to previously identified genes, we detected mutations in ERBB2, EGFR, FGFR1, PDGFRA, and MAP2K1 as potential mechanisms of primary resistance to this therapy.
Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab.
Smith et al., London, United Kingdom. In Breast, 08 Nov 2015
BACKGROUND: Trastuzumab has changed the natural history of metastatic HER2 positive breast cancer.
Natural and therapy-induced immunosurveillance in breast cancer.
Zitvogel et al., Paris, France. In Nat Med, 07 Nov 2015
In addition, the mechanism of action of targeted anticancer therapeutics, such as the erb-b2 receptor tyrosine kinase 2 (ERBB2)-targeting agent trastuzumab, involves the innate and adaptive arms of the immune system.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Sledge et al., Hamilton, Canada. In N Engl J Med, 27 Oct 2015
Methods We performed a prospective trial involving women with hormone-receptor-positive, human epidermal growth factor receptor type 2 (HER2)-negative, axillary node-negative breast cancer with tumors of 1.1 to 5.0 cm in the greatest dimension (or 0.6 to 1.0 cm in the greatest dimension and intermediate or high tumor grade) who met established guidelines for the consideration of adjuvant chemotherapy on the basis of clinicopathologic features.
Role of sphingosine 1-phosphate receptors, sphingosine kinases and sphingosine in cancer and inflammation.
Pyne et al., Bologna, Italy. In Adv Biol Regul, 25 Oct 2015
Indeed, evidence will be presented here to demonstrate that S1P4 is functionally linked with SK1 and the oncogene HER2 (ErbB2) to regulate mitogen-activated protein kinase pathways and growth of breast cancer cells.
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?
Russo et al., Palermo, Italy. In Oncotarget, 22 Oct 2015
Many biomarkers, including KRAS and NRAS mutations, BRAF mutations, PIK3CA mutations, PTEN loss, AREG and EREG expression, and HER-2 amplification have already been identified to select responders to anti-EGFR agents.
Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial.
Perez et al., Rochester, United States. In J Clin Oncol, 21 Oct 2015
PURPOSE: Significant improvement in survival outcomes has been established with the addition of trastuzumab to adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2) -positive early breast cancer treatment.
Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Horst et al., Stanford, United States. In J Clin Oncol, 08 Oct 2015
PURPOSE: The Clinical Evaluation of Pertuzumab and Trastuzumab (CLEOPATRA) study showed a 15.7-month survival benefit with the addition of pertuzumab to docetaxel and trastuzumab (THP) as first-line treatment for patients with human epidermal growth factor receptor 2 (HER2) -overexpressing metastatic breast cancer.
[Pharmacokinetic issues on cancer pharmacotherapy].
Tanigawara, In Nihon Rinsho, Aug 2015
In this chapter, two examples are presented; anti-HER2 antibody and tyrosine kinase inhibitor.
The role of taxanes in triple-negative breast cancer: literature review.
De Laurentiis et al., Trieste, Italy. In Drug Des Devel Ther, Dec 2014
Triple-negative BCs are characterized by the negative estrogen and progesterone receptors and negative HER2, and represent 15% of all BCs.
Lead Optimization of 2-Cyclohexyl-N-[(Z)-(3-methoxyphenyl/3-hydroxyphenyl) methylidene]hydrazinecarbothioamides for Targeting the HER-2 Overexpressed Breast Cancer Cell Line SKBr-3.
Al-Omar et al., Riyadh, Saudi Arabia. In Molecules, Dec 2014
UNASSIGNED: Lead derivatives of 2-cyclohexyl-N-[(Z)-(3-methoxyphenyl/3-hydroxyphenyl) methylidene]hydrazinecarbothioamides 1-18 were synthesized, characterized and evaluated in vitro against HER-2 overexpressed breast cancer cell line SKBr-3.
Quantitation of the effect of ErbB2 on epidermal growth factor receptor binding and dimerization.
Pike et al., Saint Louis, United States. In J Biol Chem, 2012
a molecular explanation for the apparent preference of the EGF receptor for dimerizing with ErbB2 and suggest that the phosphorylation of ErbB2 occurs largely in the context of the EGFR/ErbB2 heterodimer
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.
Müller et al., Hamburg, Germany. In Br J Cancer, 2012
Results show that elevated baseline sHER2 levels (>15 ng ml(1)) and a decrease of sHER2 levels (>20%) early after therapy initiation are both relevant criteria to predict response to lapatinib-based treatment.
HER2 status determination using RNA-ISH--a rapid and simple technique showing high correlation with FISH and IHC in 141 cases of breast cancer.
García-Caballero et al., Santiago de Compostela, Spain. In Histol Histopathol, 2012
The probe developed for RNA-ISH represents a viable, effective possible alternative to FISH and IHC for analysing HER2 status in primary breast tumours.
[HER-2/neu-testing in breast cancer: is the immunocytochemistry competent?].
Povilaĭtite et al., In Arkh Patol, 2012
Her-2/neu-testing in breast cancer: is the immunocytochemistry competent
[Different Her-2 status in infiltrative and intraductal components of the breast cancer].
Petrov et al., In Arkh Patol, 2012
Different Her-2 status in infiltrative and intraductal components of the breast cancer
More papers using erbB-2 antibodies
Treatment of eccrine porocarcinoma with metastasis to the parotid gland using intensity-modulated radiation therapy: a case report
Hoque Mohammad O., In PLoS ONE, 2009
... Tucson, AZ), PR (1E2, prediluted, Ventana Medical Systems), EGFR (3C6, prediluted, Ventana Medical Systems), and HER2 (4B5, prediluted, Ventana Medical Systems).
Novel design principles enable specific targeting of imaging and therapeutic agents to necrotic domains in breast tumors.
Lebedeva Irina V., In PLoS ONE, 2009
... In these experiments, two different Affibody® molecules (Affibody, Stockholm, Sweden) were used: HER2-specific Affibody (His6-Z ...
p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC
Vyzula Rostislav et al., In Diagnostic Pathology, 2009
... The expression of HER2 protein was determined by DAKO Herceptest (DAKO, Sweden) and ...
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer
Chen Wei et al., In Breast Cancer Research : BCR, 2009
... Phospho-specific HER2 antibodies (Y877, Y1221/1222 and Y1248) were also purchased from Cell Signaling.
Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype.
Falciani Francesco, In PLoS ONE, 2009
... Immunohistochemistry (IHC) status was available on most samples for ER (positivity cut-off: 10%), ERBB2 (0–3+ score, DAKO HercepTest, with >1+ defined ...
Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid
Brünner Nils et al., In Histopathology, 2008
... The investigated antibodies are components of different IHC-based HER2 tests: PATHWAY® HER2 (clone 4B5; Ventana Medical Systems Inc., Tucson, AZ, USA), ...
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Richardson Andrea L et al., In Breast Cancer Research : BCR, 2008
... (SP1 antibody, Neomarkers, Fremont, CA, USA), PR (PgR 636 antibody, Dako, Carpinteria, CA, USA) and HER2 (A085 antibody, Dako).
Pharmacokinetics and metabolism of the putative cancer chemopreventive agent cyanidin-3-glucoside in mice
Luo Jia et al., In Molecular Cancer, 2008
... and ErbB2 (polyclonal) antibodies were purchased from Cell Signaling Technology Inc ...
The protein-tyrosine kinase Syk interacts with TRAF-interacting protein TRIP in breast epithelial cells
Harrison D J et al., In British Journal of Cancer, 2008
... HER2 FISH PharmDx; Dako, Ely, Cambridge, UK) ...
Multiphoton time-domain fluorescence lifetime imaging microscopy: practical application to protein–protein interactions using global analysis
Kong Anthony et al., In Oncotarget, 2008
... Anti-HER2 antibodies recognizing the intracellular residues were obtained from Cell Signaling Technology ...
Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH
Domagala Wenancjusz et al., In Virchows Archiv, 2008
... Expression of HER-2 and c-kit was tested using the HercepTest kit (Dako) and c-kit pharmDx kit ...
HER2 status and benefit from adjuvant trastuzumab in breast cancer
Erşahin Çağatay et al., In Pathology Research International, 2007
... IHC analysis of ER, PR, and HER2 was performed on the Benchmark XT staining module (Ventana Medical Systems Inc, Tucson, AZ) ...
Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3-05) [abstract]
De Laurentiis Michele et al., In Breast Cancer Research : BCR, 2007
... HER2 expression was assessed by immunohistochemistry with the polyclonal Dako test (Dako, Glostrup, Denmark) ...
The t10,c12 isomer of conjugated linoleic acid stimulates mammary tumorigenesis in transgenic mice over-expressing erbB2 in the mammary epithelium.
Bauer Joseph Alan, In PLoS ONE, 2006
... Antibodies against HER2 were obtained from Abcam (Cambridge, MA) for Western ...
Standardization of HER2 testing: results of an international proficiency-testing ring study
Kay Elaine et al., In Histopathology, 2006
... The cases supplied from Beaumont Hospital were assessed for HER-2 protein expression using Dako HercepTest® ( ...
A case of primary small cell carcinoma of the breast
Bergkvist Leif et al., In Pathology Research International, 2006
... antibodies were used: estrogen receptor (Novocastra, clone 6F11, 1 : 100), progesterone receptor (Novocastra, clone 16, 1 : 100), c-erbB-2 oncoprotein (Dako, HER-2), mammoglobin (Dako, clone ...
Pterostilbene induces apoptosis and cell cycle arrest in human gastric carcinoma cells
Chen Wei-Jen et al., In Evidence-based Complementary and Alternative Medicine : eCAM, 2006
... -actin, HER3 and HER2 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) ...
LIV-1 suppression inhibits HeLa cell invasion by targeting ERK1/2-Snail/Slug pathway
Brandt B H et al., In British Journal of Cancer, 2006
... ductal invasive grade 2 and 3 breast cancer cases with very similar protein expression pattern (ER-positive, PR-positive, erbB2 0–2, Dako-Score/no-erbB2-amplification, EGFR-negative, p53 0–1, Ck ...
Prediction of breast tumor size by mammography and sonography--A breast screen experience
Flynn Edward R et al., In Breast Cancer Research : BCR, 2006
... Anti-Her2 antibody was purchased from Bender MedSystems (now part of eBioscience, ...
Lowering of tumor interstitial fluid pressure reduces tumor cell proliferation in a xenograft tumor model.
Najbauer Joseph, In PLoS ONE, 2005
... HER2- and Taq-specific Affibody Cloning, Overexpression, and Purification ...
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Kiessling Rolf et al., In Journal of Translational Medicine, 2005
... Her2 status was routinely determined by immunohistochemistry using the antibodies CB11 (Ventana, and from 2007 Novocastra Leica, Wetzal, Germany), A485 (DAKO, ...
A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells
Chernoff Jonathan et al., In Oncogene, 2005
... Monoclonal anti-ErbB2 was from Ventana Medical Systems, monoclonal anti-hemagglutinin (HA) (12CA5) ...
OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine
Capala Jacek et al., In European Journal of Nuclear Medicine and Molecular Imaging, 2004
... HER2:342–Cys Affibody molecule was conjugated with ...
Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells
Brodie A M H et al., In British Journal of Cancer, 2004
... The p-HER2 was purchased from Upstate (Temecula, CA, USA) and AR (SC-441) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) ...
Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation.
Koch Karl-Wilhelm, In PLoS ONE, 2003
... Polyclonal rabbit anti phosphorylated ErbB1 (Tyr1068) and phosphorylated ErbB2 (Tyr1248) were purchased from Cell Signaling technology ...
Expression of luminal and basal cytokeratins in human breast carcinoma
Pogoda Katarzyna et al., In Journal of Neuro-Oncology, 2003
... 6F11, Novocastra, dilution scale 1:100); against PR (Clone 16, Novocastra, dilution scale 1:200) and against HER2 (Polyclonal Hercep Test, DAKO).
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Anderson Steven M et al., In Breast Cancer Research : BCR, 2003
... The MMTV-c-ErbB2 (line 202) transgenic mice [ ...
Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer
Marcelo Aldaz C et al., In BMC Medical Genomics, 2003
... The data provided represent the statistical analysis of SAGE libraries from p53-Null, MMTV-erbB2 and C3(1)/SV40 transgenic mice mammary cancer models ...
The annexins
Nenutil Rudolf et al., In Breast Cancer Research : BCR, 2003
... HER2/neu immunohistochemistryDako, polyclonal ...
Hsp90 (Heat Shock Protein 90) Inhibitor Occupancy Is a Direct Determinant of Client Protein Degradation and Tumor Growth Arrest in Vivo*
Fritz Christian C. et al., In The Journal of Biological Chemistry, 2002
... Anti-Hsp90α antibody (clone 68) was from BD Biosciences; anti-Hsp90β antibody (clone H-114) and anti-HER2 (C-18) from Santa Cruz Biotechnology; and anti-EGFR, Akt (protein ...
Relationship between HER2 status and proliferation rate in breast cancer assessed by immunohistochemistry, fluorescence in situ hybridisation and standardised AgNOR analysis
Ashankyty Ibraheem M. et al., In Pathology Research International, 2002
... hours in a humidity chamber using the following dilutions: p53 (clone DO-7, titer 1 : 50, Dako, Denmark), HER-2/neu (titer 1 : 50, Dako, Denmark), ER (clone 1D5, ...
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm
Ghani Farooq et al., In Breast Cancer Research, 2002
... Patients eligible for participation were women with metastatic breast cancer who had HER2/neu overexpression as determined by immunohistochemistry (scores of 2+ or 3+ on the Dako Herceptest, Dako Corp, Carpinteria, ...
MHC class I negative phenotype of disseminated tumor cells in bone marrow is associated with poor survival in R0M0 breast cancer patients
Kono K et al., In British Journal of Cancer, 2000
... Phycoerythrin (PE)-conjugated mouse anti-HER2/neu antibody (Becton Dickinson, Franklin Lakes, NJ, USA), ...
EGFR related peptides and their cognate receptors in breast cancer
Thomas Shaji et al., In International Journal of Breast Cancer, 2000
... Immunohistochemistry for HER2-neu (Diagnostic biosystems HER2-neu, CD11 clone) ...
Untangling the ErbB signalling network
Agus D B et al., In British Journal of Cancer, 2000
... Antibodies were purchased as follows: EGFR (#2232), HER2 (#2242), pEGFR (#2236), pHER2 (#2249) and pMAPK (#9101) from Cell Signaling Technology (Beverly, MA, USA), ...
Assessment of methods for tissue-based detection of the Her-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry
Vijay Anand Reddy P. et al., In The Indian Journal of Medical Research, 1999
... immunostaining was performed using rabbit anti-human c-erbB-2 oncoprotein as primary antibody (Dako, Copenhagen, Denmark) at 1 : ...
A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data
Bertucci François et al., In Breast Cancer Research : BCR, 1999
... The HER2 status was evaluated with the Dako scale (HercepTest kit scoring ...
Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression
Eppenberger-Castori Serenella et al., In Breast Cancer Research, 1999
... EIA ErbB-2 positive samples correlate strongly with DAKO 3+ and with ErbB-2 ...
Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding.
Lamartiniere Coral A. et al., In Environmental Health Perspectives, 1998
... A colony of mouse mammary tumor virus (MMTV)-erbB2/neu transgenic mice [FVB/N-TgN(MMTV-neu202Mul)] was established ...
c-Src is required for oxidative stress-mediated activation of big mitogen-activated protein kinase 1.
Blagosklonny Mikhail V., In PLoS ONE, 1996
... HER2 was analyzed using the Dako Herceptest kit (DakoCytomation, Carpinteria, ...
Mechanisms of cellular penetration and nuclear localization of an anti-double strand DNA autoantibody
Kim Yong-Sung et al., In Nucleic Acids Research, 1995
... and Her218 was placed between the ATG start codon and EGFP coding sequence in the pEGFP-N1 plasmid (Clontech), resulting in pG ...
Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up
Meneses-Garcia A. et al., In ISRN Oncology, 1991
... Immunohistochemical staining for the HER2 protein was performed using the DAKO HercepTest immunocyto-chemical assay (DAKO, ...
Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression
Hamad Mohammad Al et al., In Breast Cancer Research, 1989
... primary antibodies against ER and PR (Biogenex, San Ramon, Ca, USA) was 1:130, and for Her-2/neu (Dako, Carpintera, Ca, USA) 1:50 ...
Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness
Blankenstein Thomas et al., In The Journal of Experimental Medicine, 1989
... Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune ...
Integration and generalization of Kappa for multiple raters
Kreipe H. H. et al., In Virchows Archiv, 1979
... IHC immunostaining was conducted using HercepTest™ (Dako Denmark A/S, Glostrup, Denmark) and/or the PATHWAY® HER2/neu (4B5) antibody (Ventana Medical Systems SA, Illkirch, France) ...
share on facebooktweetadd +1mail to friends